Asia
The two companies will invest as partners in global medtech enterprises with the goal of accelerating their market entry and commercialization in China.
Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
Will this new buy be enough for Celgene investors?
Perennial Real Estate of Singapore announced a $1.2B joint venture to develop hospital-centered mixed-use developments in China.
Beijing’s Genetron Health, a precision medicine oncology company, raised over $61M in a Series C round led by Zhongjin Kangrui Medical Industrial Fund.
Zhejiang DTRM Biopharma announced a $60M Series A round that will support clinical trials of its lead cancer candidate, a Bruton’s tyrosine kinase inhibitor.
Genostics will acquire China rights to Oncimmune’s blood-based cancer testing platform in return for a $13.5M investment into the UK-based company’s shares.
The financing was co-led by Advantech Capital and SDIC Venture Capital.
The agreement covers employees who agree to leave voluntarily.
PRESS RELEASES